Background: Regular hemodialysis patients are at an increased risk of developing anemia due to multiple causes. Some research has suggested that hypozencemia may contribute to anemia in regular hemodialysis patients. Objective: Evaluation of the effect of zinc supplementation in the treatment of anemia in regular hemodialysis patients with hypozencemia. Patients and methods: An intervention study(open labeled) that was conducted on 54 anaemic regular hemodialysis patients with hypozencemia was divided into 2 groups: group I (zinc supplementation group), which included 27 cases, and group II (control group), which included 27 controls. All patients were followed up for 6 months. Results: post-zinc treatment, group 1 showed a statistically significant increase in serum zinc level, whereas group 2 showed no statistically significant difference in serum zinc level (p<0.05 ). Serum iron and transferrin saturation showed no statistically significant difference before and after follow-up in both groups(p>0.05 ). haemoglobin level showed a statistically significant increase between baseline and six months. meanwhile, after 3 to 6 months, there was a statistically significant increase in haemoglobin in group 1 compared to group 2(p<0.05 ). There was no statistically significant difference between the two groups regarding hemoglobin , serum zinc, C-reactive protein, ferritin, and erythropoietin resistance index before the start of the study(p>0.05 ).. Erythropiotine dosage showed a statistically significant decrease from baseline to 6 months in group I(p<0.05 ). Conclusion: Oral zinc supplementation, when used as an adjuvant therapy, may have a positive impact on haemoglobin levels and erythropiotine, utilisation in hemodialysis patients with hypozencemia.